Open AccessAssessment of chemotherapy regimens on radiation pneumonitis in patients with unresectable stage III non‐small‐cell lung cancer after definitive chemoradiotherapy
Author(s) -
Tadashi Sakaguchi,
Kentaro Ito,
Naoki Furuya,
Kei Morikawa,
Kentaro Fujiwara,
Yoichi Nishii,
Tatsuya Inoue,
Osamu Hataji,
Masamichi Mineshita
Publication year - 2021
Publication title -
thoracic cancer
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.823
H-Index - 28
eISSN - 1759-7714
pISSN - 1759-7706
DOI - 10.1111/1759-7714.14005
Subject(s) - medicine , pemetrexed , carboplatin , durvalumab , chemoradiotherapy , regimen , pneumonitis , radiation therapy , chemotherapy , cisplatin , oncology , lung cancer , cancer , lung , pembrolizumab , immunotherapy
Consolidation therapy with durvalumab after concurrent chemoradiotherapy has been reported to significantly prolong progression-free survival and overall survival in patients with stage III unresectable non-small cell lung cancer (NSCLC). However, which chemotherapy regimen should be selected for consolidation therapy with durvalumab is currently unknown.